Clinical Trial

PreveCeutical Enters into Loan Agreements

Vancouver, British Columbia--(Newsfile Corp. - June 17, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company"…

2 years ago

FindMyClinicalTrial Inc. Collaborates With Mayo Clinic on Clinical Trial Software

WASHINGTON, DC / ACCESSWIRE / June 17, 2024 / FindMyClinicalTrial Inc. (FMCT), a digital health startup company building patient engagement…

2 years ago

T1D Exchange Announces 21 Real-World Data Presentations at the American Diabetes Association (ADA) 84th Scientific Sessions

-       Company invited to speak during three symposia on the impact of quality improvement, the cost of disparities in diabetes…

2 years ago

CluePoints Continues ‘Turning Artificial Intelligence into Human Intelligence’ by Launching Two New Innovations

Site Profile & Oversight Tool (SPOT) and Intelligent Medical Coding (IMC) unveiled by RBQM innovator at DIA Global Annual Meeting…

2 years ago

PhaseV Launches New Version of its Machine Learning Platform, Facilitating Increased Adoption of Adaptive Clinical Trials

AdaptV Platform Optimizes Trial Design Across Teams With New Capabilities to Improve Group Sequential Design, Response Adaptive Randomization and BOIN…

2 years ago

Labcorp Launches Global Trial Connect to Accelerate Clinical Trials

Suite of digital and data solutions designed to improve clinical trial efficiency, reduce data delays and simplify investigator site workflows…

2 years ago

iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer

WATERTOWN, Mass. and GOSSELIES, Belgium, June 17, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical…

2 years ago

Longeveron Announces Exercise of Warrants for $4.4 Million Gross Proceeds

MIAMI, June 17, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage regenerative medicine biotechnology…

2 years ago

Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension

AV-101 did not meet the primary endpoint of change in pulmonary vascular resistance (PVR) for any of the studied dosesWALTHAM,…

2 years ago